These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2041034)

  • 21. The effect of exercise on intra-arterial blood pressure and pulse rate before and during long-term high-dose treatment with labetalol in patients with severe, therapy-resistant hypertension.
    la Cour Petersen E; Kristensen BO
    Postgrad Med J; 1980; 56 Suppl 2():60-4. PubMed ID: 7433345
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of labetalol in hypertension during exercise and postural changes.
    Balasubramanian V; Mann S; Millar-Craig MW; Raftery EB
    Br J Clin Pharmacol; 1979; 8(Suppl 2):95S-100S. PubMed ID: 526410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol.
    Falliers CJ; Vrchota J; Blasucci DJ; Maloy JW; Medakovic M
    J Clin Hypertens; 1985 Mar; 1(1):70-9. PubMed ID: 3836297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood pressure, plasma volume, extracellular volume and glomerular filtration rate during treatment with labetalol in essential hypertension.
    Rasmussen S; Nielsen PE
    Postgrad Med J; 1980; 56 Suppl 2():33-6. PubMed ID: 7433340
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of propranolol and labetalol on renal haemodynamics at rest and during exercise in essential hypertension.
    Pedersen EB; Larsen JS
    Postgrad Med J; 1980; 56 Suppl 2():27-32. PubMed ID: 7433339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On the combination of alpha- and beta-adrenoceptor blockade in hypertension.
    Stokes GS; Mennie BA; Gellatly R; Hill A
    Clin Pharmacol Ther; 1983 Nov; 34(5):576-82. PubMed ID: 6627819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beta blockade and intermittent claudication.
    Lepäntalo M
    Acta Med Scand Suppl; 1985; 700():1-48. PubMed ID: 2865873
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postmarketing comparison of labetalol and propranolol in hypertensive patients.
    Due DL; Giguere GC; Plachetka JR
    Clin Ther; 1986; 8(6):624-31. PubMed ID: 3791361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of the hemodynamic effects of labetalol and sodium nitroprusside in patients undergoing carotid endarterectomy.
    Geniton DJ
    AANA J; 1990 Aug; 58(4):281-7. PubMed ID: 2399780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Felodipine compared to prazosin as additional therapy to a beta-blocking drug.
    Chalmers J; Wing L; West M; Bune A; Johnston C; Jackson B; McGrath B; Mashford ML; Heath W; Westwood B
    J Cardiovasc Pharmacol; 1987; 10 Suppl 10():S82-4. PubMed ID: 2455150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Favourable interaction of calcium antagonist plus ACE inhibitor on cardiac haemodynamics in treating hypertension: rest and effort evaluation.
    Di Somma S; Carotenuto A; de Divitiis M; Paulucci A; Galderisi M; Cuocolo A; de Divitiis O
    J Hum Hypertens; 1995 Mar; 9(3):163-8. PubMed ID: 7783096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of prazosin and labetalol on blood pressure control and blood lipid levels in patients with mild-to-moderate essential hypertension.
    Farry JP; Fischl SJ; Tighe MJ; Krell MJ
    Am J Med; 1989 Jan; 86(1B):41-4. PubMed ID: 2643864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of labetalol in general medicine in aged patients with hypertension. Compliance, efficacy and safety in long-term treatment].
    Hugonot R; Hugonot L; Herrero G
    Ann Cardiol Angeiol (Paris); 1990 Nov; 39(9):547-53. PubMed ID: 2291621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Efficacy of and tolerance to prolonged release prazosin in patients with hypertension and non-insulin dependent diabetes].
    Hanon O; Giacomino A; Troy S; Bernaud C; Girerd X; Weber S
    Ann Cardiol Angeiol (Paris); 2000 Oct; 49(7):390-6. PubMed ID: 12555491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results obtained from labetalol therapy in essential hypertension.
    Cagatay G; Soydan I
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):110-2. PubMed ID: 3557731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients.
    Besterman EM; Spencer M
    Br J Clin Pharmacol; 1979; 8(Suppl 2):205S-209S. PubMed ID: 526402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of labetalol and prazosin in hypertensive patients using automated ambulatory monitoring.
    Gray JM; Silberman HM; Gorwit JI
    Am J Med; 1988 May; 84(5):904-10. PubMed ID: 3284341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise.
    Lund-Johansen P; Omvik P; Haugland H
    Br J Clin Pharmacol; 1986; 21 Suppl 1(Suppl 1):45S-54S. PubMed ID: 2939867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of labetalol on systemic and pulmonary haemodynamics at rest and during exercise in hypertensive patients.
    Fagard R; Amery A; Reybrouck T; Lijnen P; Billiet L
    Clin Sci Mol Med Suppl; 1978 Dec; 4():279s-281s. PubMed ID: 282068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of labetalol on platelet aggregation in hypertensive patients.
    Lin MS; Huang CS
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):391-3. PubMed ID: 1748539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.